Arbutus Q2 2026: $178M Moderna Payment, $230M Buyback, and New Patent Suits
ABUS sits 37% above its 52-week low of $3.31.
Summary
Arbutus Biopharma reported Q2 2026 results, confirmed receipt of $178.4 million from the Moderna settlement, filed new patent lawsuits against Pfizer and BioNTech, and announced plans to return up to $230 million to shareholders.
Key Events · Earnings and Guidance · ABUS
-
Q2 2026 Financial Results
For the second quarter, the company posted a net loss of $5.1 million, or $0.03 per share, on revenue of $1.0 million. Cash and investments stood at $92.6 million as of June 30, 2026.
-
Moderna Settlement Payment Received
In July 2026, Arbutus received $178.4 million as its share of the $950 million noncontingent payment, with an additional $1.3 billion contingent payment still possible.
-
New Patent Lawsuits Filed
Three international lawsuits were filed against Pfizer and BioNTech in July 2026, seeking to enforce LNP technology patents across 21 countries.
-
FDA Alignment on Imdusiran Phase 2b
The company reached alignment with the FDA on the design and safety parameters of a proposed Phase 2b clinical trial for imdusiran in chronic hepatitis B.
Analysis · ABUS · Life Sciences
Arbutus delivered its Q2 2026 financials alongside a series of material updates. The company has now received $178.4 million from the Moderna settlement, launched new international patent lawsuits against Pfizer and BioNTech, secured FDA alignment on a pivotal trial design, and outlined a $230 million capital return to shareholders. With a pre-payment cash position of $92.6 million, the repurchase plan underscores management's confidence in the company's valuation. The convergence of litigation progress, clinical advancement, and shareholder-friendly capital allocation makes this a notable update for investors.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1645 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABUS was trading at $4.52 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $922.5M. The 52-week trading range was $3.31 to $5.38. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.